Impact of a programme of mass mammography screening for breast cancer on socio-economic variation in survival: a population-based study by Louwman, W. J. et al.
EPIDEMIOLOGY
Impact of a programme of mass mammography screening
for breast cancer on socio-economic variation in survival:
a population-based study
W. J. Louwman Æ L. V. van de Poll-Franse Æ
J. Fracheboud Æ J. A. Roukema Æ J. W. W. Coebergh
Received: 16 November 2006/Accepted: 25 November 2006/Published online: 9 January 2007
  Springer Science+Business Media B.V. 2006
Abstract
Background After a systematic mass mammography
breast cancer screening programme was implemented
between 1991 and 1996 (attendance 80%), we evalu-
ated its impact on survival according to socioeconomic
status (SES).
Methods We studied survival rates up to 1-1-2005 for
all consecutive breast cancer patients aged 50–69 and
diagnosed in the period 1983–2002 in the area of the
Eindhoven Cancer Registry (n = 4939). Multivariate
analyses were performed using Cox regression analysis.
Results The proportion of breast cancer patients with
a low SES decreased from 22% in 1983–1990 to 14% in
1997–2002 when attendance was 85%. The proportion
of newly diagnosed patients with stage III or IV disease
in 1997–2002 was only 10% compared to 14% in 1991–
1996 and 26% in 1983–1989 (P < 0.0001). Stage dis-
tribution improved for all socio-economic groups
(P = 0.01). Survival was similar for all socio-economic
groups in 1983–1990, but after the introduction of the
screening programme women with low SES had lower
age- and stage-adjusted survival rates (HR 2.0, 95%CI:
1.3–3.0). Survival was better for patients diagnosed in
1997–2002 compared to 1983–1990 for all socioeco-
nomic strata; it was substantially better for the high
SES group (HR 0.36, 0.2–0.5) compared to the lowest
SES (HR 0.77, 0.6–1.1).
Conclusion Although survival improved for women
from each of the socio-economic strata, related to the
high participation rate of the screening programme,
women from lower socio-economic strata clearly ben-
eﬁted less from the breast cancer screening pro-
gramme. That is also related to the higher prevalence
of comorbidity and possibly suboptimal treatment.
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Introduction
Mammography screening aims at early detection of
breast cancer so that adequate treatment will eventu-
ally lower breast cancer mortality. In a mass screening
programme, it is therefore especially important to
reach women who have the highest chance of being
diagnosed with advanced stage or have the lowest
survival rates.
Women from lower socio-economic strata are less
likely to attend population screening programmes
[1–4] and are also more likely to present with
unfavourable stage at diagnosis, [1, 5, 6] although not
all studies conﬁrm this [7–9]. Lower breast cancer
survival rates among the disadvantaged are usually
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to suboptimal access to adequate treatment. A recent
population-based study in Switzerland found social
class to be an independent prognostic factor [10].
The mass breast cancer screening programme was
introduced in 1991 for women of 50–69 years and
became fully implemented in 1996 in the south of
the Netherlands covered by the population-based
Eindhoven Cancer Registry, with a continuous high
participation rate. Based on previous work [11] and a
new postcode-based indicator of socio-economic status
(SES) introduced by Statistics Netherlands [12]w e
were able to investigate survival according to SES for a
sufﬁcient period of time after introduction.
We studied whether survival according to SES was
affected differentially by the implementation of the
screening programme.
Methods
The Eindhoven Cancer Registry records data on all
patients newly diagnosed with cancer in the south–
eastern part of the Netherlands, an area with now
2.4 million inhabitants (about 15% of the Dutch pop-
ulation) and only general hospitals. Trained registry
personnel actively collect data on diagnosis, staging,
and treatment from the medical records after notiﬁ-
cation by pathologists and medical registration ofﬁces.
In the area of the Eindhoven Cancer Registry, a
biennial breast cancer screening programme for wo-
men aged 50–69 years was started in 1991 and fully
implemented in 1996. The attendance rate was more
than 80% [13].
For our analyses we included all patients age
50–69 years diagnosed in 1983–2002 with invasive
breast cancer in the eastern part of the registration
area (about 1 million inhabitants). This population
has been followed-up for vital status up to 1-1-2005.
Information on the vital status of all patients was
obtained initially from the municipal registries and
since 1998 from the Central Bureau for Genealogy.
These registers provide virtually complete coverage of
all deceased Dutch citizens.
An indicator of socioeconomic status was developed
by Statistics Netherlands [12] being based on individual
ﬁscal data from the year 2000 on the economic value of
the home and household income and provided at
aggregated level for each postal code (average of 17
households). Socioeconomic status was categorized
according to quintiles ranging from 1 (low) to 5 (high),
with a separate class for postal codes with a care-pro-
viding institution (such as a nursing home). This
measure is assumed to be valid ten years before and
after the basic year (2000), so for patients diagnosed
before 1990 we used a measure which was also based
on postal code of residence, but socio-economic status
(ﬁve categories) was based on data from a marketing
agency (self-reported occupation and education deﬁne
45 social classes, collapsed into a 5-level indicator
based on average number of years of education), as
described before [11]. We also used both SES indica-
tors for the whole study period (1983–2002) to make
sure any effect of diagnostic period was not attribut-
able to the indicator we used.
We calculated distribution of age and stage of
disease according to period of diagnosis.
Stage was categorized according to the TNM classi-
ﬁcation[14].Patientswitheitherpositivelymphnodesor
metastases were considered to have advanced disease.
Chi-square test was performed of changes in the
distribution across the three diagnostic periods. T-tests
were performed of differences between two groups.
Crude survival analyses were performed. The log-
rank test was used to evaluate signiﬁcant differences
between survival curves in univariate analyses. We
used Cox regression models to compute multivariate
rates. The proportional hazard assumption of the pre-
dictor was evaluated by applying Kaplan–Meier
Curves. The predictor satisﬁed the assumption of pro-
portionality as the graphs of the survival function
versus the survival time resulted in graphs with parallel
curves as did the graphs of the log(–log(survival))
versus log of survival time. The independent prognostic
effect of SES was investigated, adjusting for age and
stage of disease, and stratiﬁed according to period of
diagnosis (1983–1990, 1991–1996, 1997–2002). We also
calculated the age and stage-adjusted effect of period
of diagnosis stratiﬁed according to SES.
Results
Median age was similar for all three periods of diag-
nosis (59, 60, and 59 years, respectively).
Patients diagnosed between 1997 and 2002 had a
signiﬁcantly more favourable stage at diagnosis than
patients diagnosed in earlier periods (P < 0.0001): the
proportion diagnosed with stage I (tumour smaller
than 2 cm, no axillary lymph nodes involved) increased
from 30% in 1983–1990 to 41% in 1991–1996 and 45%
in more recent years (Table 1). The proportion with
advanced disease, i.e. stage III or IV, was signiﬁcantly
lower in the most recent period (9.7%) compared to
1991–1996 (14%) and 1983–1989 (26%, P < 0.0001).
Treatment varied over time, with a large proportion
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123receiving systemic therapy in recent years (50%, vs.
36% and 29%).
The proportion of patients from the lowest socio-
economic class decreased from 22% in 1983–1990 to
18% in 1991–1996 and 14% in 1997–2002 (P < 0.0001),
whereas the proportion from in the higher social clas-
ses increased.
Stage distribution improved signiﬁcantly over time
for each social class (P < 0.01). It was similar for all
SES groups in 1983–1990 (P = 0.7, Fig. 1), although
the proportion with stage IV was somewhat lower in
the highest classes. The stage distribution was mar-
ginally more favourable for high SES compared to the
lowest SES group in both 1991–1996 and 1997–2002
(P = 0.06 both periods), although the overall effect of
SES on stage was not signiﬁcant in the last period of
time (P = 0.4).
Survival improved for all socio-economic strata over
time (Fig. 2). Survival rates did not differ among
patients from each of the socio-economic classes
Table 1 Characteristics of all women age 50–69 years diagnosed with invasive breast cancer between 1983–2002 in Southeastern
Netherlands
1983–1990 1991–1996 1997–2002 Total
n % n % n % n %
TNM
I 465 30 642 41 838 45 1,945 39
II 638 42 665 43 805 44 2,108 43
III 278 18 152 10 115 6.2 545 11
IV 115 7.5 68 4.4 65 3.5 248 5.0
unknown 38 2.5 31 2.0 24 1.3 93 1.9
Treatment*
S alone 271 18 341 22 249 13 861 17
S + RT 766 50 628 40 658 36 2,052 42
S + RT + ST 305 20 422 27 673 36 1,400 28
S + ST 108 7 123 8 231 13 462 9.4
ST alone 26 1.7 23 1.5 23 1.3 72 1.5
Other 58 3.8 21 1.4 13 0.7 92 1.9
Socio-economic status
1 (low) 336 22 285 18 262 14 883 18
2 325 21 319 20 342 19 986 20
3 308 20 279 18 355 19 942 19
4 154 10 274 18 358 19 786 16
5 (high) 302 20 315 20 414 22 1,031 21
institution# 0 0.0 23 1.5 33 1.8 56 1.1
unknown 109 7.1 63 4.0 83 4.5 255 5.2
Total 1,534 1,558 1,847 4,939 100
* S = Surgery, RT = Radiotherapy, ST = Systemic therapy
#institution = care-providing institution such as a nursing home
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Fig. 1 Stage distribution
according to socio-economic
status and period of diagnosis
of patients age 50–69 years
with invasive breast cancer in
Southeastern Netherlands
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123diagnosed 1983–1990 in the period (P = 0.9), 5-year
survival rates being 70%, 70%, 70%, 68% and 69% for
patients from the lowest to the highest social class,
respectively. For patients diagnosed in 1991–1996,
survival of patients with a high SES was better than
that of all other socio-economic strata (P = 0.01),
5-year survival rates being 76%, 76%, 80%, 78%, and
87%, respectively. For patients diagnosed in 1997–2002
an increasing gradient in survival was observed
(P = 0.002) ranging from the lowest rates for the low-
est SES group to the highest for the higher classes
(80%, 84%, 83%, 85%, and 89%, respectively).
Multivariate analysis (Table 2) showed that patients
diagnosed between 1991 and 1996 from the lower
socialclasseshada29%higherriskofdeathcomparedto
thehighestsocio-economicgroup,afteradjustingforage
and stage at diagnosis (HR for the lowest versus the
highest SES group: 1.29, 95%CI: 1.0–1.7). The risk of
death for low SES patients diagnosed since 1997 was
twiceashighasthatforthehighestSESgroup(HR:2.01,
95%CI: 1.3–3.0). The overall effect of socio-economic
status was signiﬁcant in the last period (P = 0.02).
Additionaladjustmentfortreatmentdidnotchangerisk
estimates more than 5% (data not shown).
Age and stage-adjusted survival improved over
time for all socioeconomic strata (Table 3), the larg-
est improvements were found for the highest social
classes.
Fig. 2 Trend in survival
according to socio-economic
status for all women age 50–
69 years diagnosed with
invasive breast cancer in
Southeastern Netherlands
Table 2 Multivariate regression analysis of survival of breast cancer patients age 50-69 years according to period of diagnosis,
Southeastern Netherlands
1983–1990 1991–1996 1997–2002
HR*
a 95% CI HR*
a 95% CI HR*
a 95% CI
Age (continuous) 1.03 1.0–1.0 1.04 1.0–1.1 1.01 1.0–1.0
Socio-economic status
1 (low) 1.01 0.8–1.2 1.29 1.0–1.7 2.01 1.3–3.0
2 1.03 0.8–1.3 1.28 1.0–1.7 1.54 1.0–2.3
3 0.95 0.8–1.2 1.18 0.9–1.6 1.53 1.0–2.3
4 0.99 0.8–1.3 1.39 1.0–1.8 1.33 0.9–2.0
5 (high)
b 1.00 1.00 1.00
C
2 trend 0.58 (P = 0.97) 5.9 (P = 0.21) 11.4 (P = 0.02)
TNM stage
I
b 1.00 1.00 1.00
II 1.75 1.5–2.1 2.33 1.9–2.9 2.00 1.4–2.8
III 3.11 2.5–3.8 4.67 3.5–6.2 5.39 3.6–8.1
IV 9.85 7.6–13 16.0 12–22 16.5 11–24
unknown 2.25 1.4–3.5 2.56 1.4–4.6 4.81 2.3–10
* HR = Hazard Ratio, CI = Conﬁdence Interval
a Adjusted for all variables listed
b Reference
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123Discussion
We found that the proportion of breast cancer patients
with a low SES has decreased since the introduction of
a mass biennial mammography screening programme
with high response rates. Although stage distribution
improved for all socio-economic groups, the propor-
tion with advanced disease decreased the most in the
highest socio-economic group. In the 1980s survival
was similar for all socio-economic groups, but since the
introduction of screening the survival of women with a
high SES has improved more than that for low socio-
economic classes, also after adjustment for age and
stage.
We used an indicator of socio-economic status based
on the postal code of a residential area. This aggregate
covers a relatively small geographical area, and thus
represents a reliable approximation of individual socio-
economic status. Furthermore, routinely collected in-
come tax data (no questionnaires or interviews) have
been found to provide reliable estimates of household
income. Previous studies have proven that socio-eco-
nomic differences based on neighbourhood data tend
to reﬂect socio-economic differences well at the indi-
vidual level [15–17]. Furthermore, this objective mea-
sure of SES is also applicable for older women (born
before 1955), whose occupation or education does not
always properly reﬂect their social class [18]. We also
repeated the analyses comparing both SES indicators if
they were applied for the whole study period (1983–
2002) to ensure any that effect of diagnostic period was
not attributable to the indicator we used, and it was
not.
The lower proportion of patients with a low SES
since the introduction of screening is not likely to re-
ﬂect the higher attendance rate of women from a
higher social class because of the very high participa-
tion rate, although this is not known according to social
class. Studies from other countries have shown that
SES does play a role in participation in the screening
programme, [2] sometimes [3] but not always [4] due to
the costs of a screening mammogram. However,
the costs for the mass screening programme in the
Netherlands are completely covered by public funds.
Furthermore, the mean attendance rate in the Neth-
erlands has always been rather high (about 80%), [13]
and in our study area even higher than the national
mean (85% in 2005) [19].
Foreign-born women are more likely to be non-
attenders in the Netherlands, [20] as well as in Sweden,
[21] Australia, [3] and the US, [22] for a variety of
reasons. However the incidence of breast cancer
among these groups of migrants is relatively low in the
Netherlands and the stage distribution is comparable
to that of women born in the Netherlands [20]. So this
is unlikely to have affected survival rates in our study.
A lower attendance rate of low social classes will
result in more advanced disease stages at presentation
[23]. Before the start of the mammography screening
programme, we found that the stage distribution for
breast cancers diagnosed in 1980–1989 was slightly
more favourable for the highest socio-economic group
[24]. We have now shown that this was also true after
the introduction of screening, although the differences
were small. In fact, we found that, although stage dis-
tribution became more favourable for all socio-eco-
nomic groups, the proportion with advanced disease
decreased less in the lower socio-economic group. This
differential stage distribution was also described in a
recent Danish study, [6] although our differences were
smaller.
The variation in survival according to SES may also
be related to differences in treatment, which depends
on the disease stage and varies over time. The use of
surgery and radiotherapy was similar across SES
groups. However, we found that the administration of
adjuvant chemotherapy varied across the social strata
among stage II patients (8% of the lowest SES group
Table 3 Multivariate regression analysis of survival according to socio-economic status (SES) of breast cancer patients age 50–69 years
in Southeastern Netherlands
SES 1 (low) 2 3 4 5 (high)
HR*
a 95% CI HR*
a 95% CI HR*
a 95% CI HR*
a 95% CI HR*
a 95% CI
Period of diagnosis
1983–1990
b 1.00 1.00 1.00 1.00 1.00
1991–1996 0.87 0.7–1.1 0.72 0.6–0.9 0.80 0.6–1.0 0.84 0.6–1.1 0.60 0.5–0.8
1997–2002 0.77 0.6–1.1 0.49 0.4–0.7 0.61 0.4–0.8 0.49 0.3–0.7 0.36 0.2–0.5
X
2 trend 3.21 (P = 0.21) 20.9 (P < 0.001) 9.2 (P = 0.01) 14.1 (P < 0.001) 35.6 (P < 0.001)
HR = Hazard Ratio, CI = Conﬁdence Interval
a Adjusted for age at diagnosis and stage of disease
b Reference
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123versus 17% of the highest SES group, P < 0.001). Pa-
tients with a higher SES seem to have beneﬁted more
from the general trend towards more adjuvant che-
motherapy independent of the disease stage. This may
explain, at least in part, the diverging trend in survival
rates.
Another explanation for differential survival could
be socio-economic variations in lifestyle. Smoking has
become relatively more prevalent among low SES
groups [25, 26]. This may have had an adverse effect on
survival due to a poor general health while undergoing
breast cancer treatment or to smoking related diseases
(such as chronic obstructive pulmonary diseases
(COPD) or cardiovascular disease).
Also related to an unhealthy lifestyle is obesity,
which has become an increasingly important problem
in the last decade, [27, 28] especially among women
from the lower social classes [29].
Serious concomitant diseases besides breast cancer
also affect survival rates, [30] which may explain dif-
ferences in survival if comorbidity occurs more fre-
quently in low SES groups.
Since the Eindhoven Cancer Registry has recorded
comorbidity for all newly diagnosed patients since
1993, we checked whether the prevalence varied across
socioeconomic strata. Indeed, the proportion of pa-
tients with comorbidity was higher among those with a
lower SES (70% of patients in the lowest SES group
had one or more concomitant conditions compared to
60% of the high SES group). In particular, the preva-
lence of diabetes and cardiovascular disease was
highest in the low SES groups (diabetes in 10% with
low SES and 4% with high SES, cardiovascular disease
7% and 4%, respectively).
Several studies have reported increased survival
rates after the introduction of breast cancer screening
[31-35]. As far as we know, no studies describe a dif-
ferential effect of the introduction of screening on
survival rates for socio-economic strata. However,
socioeconomic inequalities in mortality have been
widening in recent decades in western European
countries [36]. In fact, socio-economic differences in
breast cancer mortality increased between 1983 and
1993 among women in Finland and Italy (Turin), but
remained stable in Denmark and decreased somewhat
in Norway where a mass screening programme was
only introduced later [36, 37].
In conclusion, despite a very high participation rate
women from lower socio-economic strata clearly ben-
eﬁted less from the introduction of the breast cancer
screening programme than those with a lower SES,
probably due to a higher prevalence of comorbidity
and suboptimal treatment (for both the cancer and the
concomitant disease).
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